Welcome to our dedicated page for Icu Medical news (Ticker: ICUI), a resource for investors and traders seeking the latest updates and insights on Icu Medical stock.
ICU Medical reports news on its global medical-device business in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate-site and home-care settings. Company updates commonly cover quarterly results, fiscal guidance, GAAP and non-GAAP profitability measures, and revenue trends across the Consumables, Infusion Systems and Vital Care product lines.
Recurring announcements also include earnings-call schedules, investor conference participation and business changes that affect reported comparisons, including the completed divestiture of the IV Solutions business. The company’s news flow centers on product-line performance, margin trends, adjusted EBITDA, adjusted diluted earnings per share and management commentary on operating results.
ICU Medical (Nasdaq:ICUI), a leading innovator in medical product development and manufacturing, has announced its participation in two major investor conferences this September. The company's CEO, Vivek Jain, will be attending:
1. The Wells Fargo 2024 Healthcare Conference in Boston on September 4, where he will engage in one-on-one meetings.
2. The Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 6, featuring a fireside chat at 4:00 a.m. PT (7:00 a.m. ET). This discussion will be webcast live on ICU Medical's Investor Relations website and archived for future viewing.
These events provide valuable opportunities for investors to gain insights into ICU Medical's operations and future plans.
ICU Medical (Nasdaq:ICUI) reported its Q2 2024 financial results. Revenue increased to $596.5 million, up from $549.3 million in Q2 2023. GAAP gross profit rose to $207.4 million, with a gross margin of 35%. However, the company reported a GAAP net loss of $(21.4) million, or $(0.88) per diluted share, compared to a loss of $(9.9) million in Q2 2023. Adjusted diluted EPS was $1.56, down from $1.88 in the previous year. Adjusted EBITDA decreased to $91.3 million from $98.1 million.
The company updated its fiscal year 2024 guidance, narrowing the range for adjusted EBITDA to $345-$365 million and increasing the range for diluted EPS to $4.95-$5.35. Revenue growth was observed across all product lines, with Consumables showing the largest increase.
ICU Medical (Nasdaq: ICUI), a leading innovator in medical product development and manufacturing, has announced its schedule for the second quarter 2024 earnings release and conference call. The company will disclose its Q2 2024 results on Wednesday, August 7th, 2024, at approximately 4:00 p.m. ET. Following this, a conference call will be held at 4:30 p.m. ET on the same day to discuss the results.
Interested parties can access the call by dialing (800) 579-2543 and using the conference ID "ICUMED". Additionally, a simultaneous webcast will be available on the company's website at www.icumed.com. To access the webcast, navigate to the Investors tab and click on the Webcast icon. The webcast will also be available for replay after the live event.
ICU Medical, Inc. announced its First Quarter 2024 Results with revenue of $566.7 million, a slight decrease from the previous year. The GAAP gross profit was $185.2 million, with a net loss of $(39.5) million. Adjusted diluted earnings per share were $0.96, and Adjusted EBITDA was $78.8 million. Revenues by product line showed fluctuations, with Vital Care including revenue from a Pfizer contract. CEO Vivek Jain stated that the results were as expected.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.